Division of Oncology, Department of Medicine, Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St Louis, MO.
Department of Anatomic Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN.
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432242. doi: 10.1200/EDBK_432242.
Most malignant peripheral nerve sheath tumors (MPNSTs) are clinically aggressive high-grade sarcomas, arising in individuals with neurofibromatosis type 1 (NF1) at a significantly elevated estimated lifetime frequency of 8%-13%. In the setting of NF1, MPNSTs arise from malignant transformation of benign plexiform neurofibroma and borderline atypical neurofibromas. Composed of neoplastic cells from the Schwannian lineage, these cancers recur in approximately 50% of individuals, and most patients die within five years of diagnosis, despite surgical resection, radiation, and chemotherapy. Treatment for metastatic disease is limited to cytotoxic chemotherapy and investigational clinical trials. In this article, we review the pathophysiology of this aggressive cancer and current approaches to surveillance and treatment.
大多数恶性外周神经鞘瘤(MPNST)是临床上侵袭性高等级肉瘤,发生于神经纤维瘤病 1 型(NF1)个体中,估计终生发病率显著升高,为 8%-13%。在 NF1 背景下,MPNST 源自良性丛状神经纤维瘤和交界性非典型神经纤维瘤的恶性转化。这些癌症由雪旺氏细胞谱系的肿瘤细胞组成,约有 50%的个体复发,尽管进行了手术切除、放疗和化疗,但大多数患者在诊断后五年内死亡。转移性疾病的治疗仅限于细胞毒性化疗和临床试验。本文综述了这种侵袭性癌症的病理生理学以及目前的监测和治疗方法。